X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2332) 2332
Newsletter (92) 92
Newspaper Article (41) 41
Book Chapter (17) 17
Magazine Article (13) 13
Dissertation (9) 9
Publication (6) 6
Conference Proceeding (4) 4
Web Resource (2) 2
Book Review (1) 1
Streaming Video (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sitagliptin (1643) 1643
science & technology (1410) 1410
life sciences & biomedicine (1348) 1348
humans (1168) 1168
diabetes mellitus, type 2 - drug therapy (877) 877
male (859) 859
sitagliptin phosphate (836) 836
type 2 diabetes (834) 834
female (655) 655
diabetes (644) 644
middle aged (576) 576
hypoglycemic agents - therapeutic use (559) 559
endocrinology & metabolism (515) 515
pyrazines - therapeutic use (438) 438
triazoles - therapeutic use (437) 437
aged (427) 427
dipeptidyl-peptidase iv inhibitors - therapeutic use (425) 425
animals (388) 388
pharmacology & pharmacy (358) 358
treatment outcome (355) 355
research (318) 318
hypoglycemic agents (316) 316
diabetes mellitus, type 2 - blood (307) 307
adult (305) 305
glucose (304) 304
diabetes mellitus (291) 291
sitagliptin phosphate - therapeutic use (291) 291
care and treatment (273) 273
drug therapy, combination (273) 273
diabetes therapy (272) 272
hypoglycemic agents - adverse effects (259) 259
metformin (257) 257
dipeptidyl-peptidase iv inhibitors - pharmacology (251) 251
hypoglycemic agents - administration & dosage (243) 243
insulin (240) 240
blood glucose - metabolism (239) 239
drug therapy (233) 233
pyrazines - pharmacology (229) 229
triazoles - pharmacology (227) 227
analysis (225) 225
blood glucose - drug effects (218) 218
triazoles - administration & dosage (204) 204
pyrazines - administration & dosage (203) 203
hypoglycemic agents - pharmacology (196) 196
dosage and administration (191) 191
metformin - therapeutic use (188) 188
pyrazines - adverse effects (186) 186
double-blind method (184) 184
triazoles - adverse effects (184) 184
liraglutide (183) 183
glycated hemoglobin a - metabolism (180) 180
dipeptidyl-peptidase iv inhibitors - adverse effects (177) 177
type 2 diabetes mellitus (176) 176
vildagliptin (174) 174
rats (172) 172
adamantane - analogs & derivatives (168) 168
internal medicine (166) 166
general & internal medicine (162) 162
medicine, general & internal (160) 160
clinical trials (157) 157
sitagliptin phosphate - pharmacology (156) 156
dextrose (154) 154
risk factors (154) 154
diabetes mellitus, type 2 - complications (145) 145
dipeptidyl-peptidase iv inhibitors - administration & dosage (145) 145
insulin resistance (140) 140
medical research (139) 139
saxagliptin (139) 139
dipeptidyl peptidase 4 - metabolism (137) 137
glucagon (135) 135
exenatide (127) 127
abridged index medicus (125) 125
physical fitness (124) 124
medicine, experimental (123) 123
medicine & public health (122) 122
mice (122) 122
sitagliptin phosphate - adverse effects (121) 121
health aspects (120) 120
glycosylated hemoglobin (119) 119
cardiovascular system & cardiology (118) 118
hypoglycemia (118) 118
sitagliptin phosphate - administration & dosage (118) 118
glycated hemoglobin a - analysis (115) 115
medicine, research & experimental (114) 114
research & experimental medicine (114) 114
patients (113) 113
adamantane - therapeutic use (111) 111
complications and side effects (108) 108
metformin - administration & dosage (107) 107
body weight (105) 105
original (105) 105
peptides (105) 105
peptidase (103) 103
peptides - therapeutic use (103) 103
body mass index (99) 99
incretins (99) 99
venoms - therapeutic use (99) 99
diabetes mellitus, type 2 - metabolism (98) 98
linagliptin (98) 98
medicine (98) 98
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2388) 2388
German (30) 30
Japanese (27) 27
French (24) 24
Hungarian (13) 13
Korean (13) 13
Russian (13) 13
Spanish (13) 13
Portuguese (12) 12
Chinese (11) 11
Czech (11) 11
Dutch (3) 3
Italian (2) 2
Swedish (2) 2
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2019, Volume 321, Issue 15, pp. 1466 - 1480
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 378 - 388
Aims To assess the safety and efficacy of monotherapy with once‐weekly subcutaneous (s.c.) semaglutide vs sitagliptin in Japanese people with type 2 diabetes... 
GLP‐1 | sitagliptin | type 2 diabetes | GLP-1 | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glycated Hemoglobin A - analysis | Follow-Up Studies | Nausea - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diarrhea - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glucagon-Like Peptides - administration & dosage | Humans | Nausea - physiopathology | Patient Dropouts | Weight Loss - drug effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - ethnology | Glucagon-Like Peptide-1 Receptor - metabolism | Nausea - therapy | Injections, Subcutaneous | Hypoglycemia - chemically induced | Severity of Illness Index | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Drug Administration Schedule | Administration, Oral | Japan | Constipation - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Constipation - chemically induced | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diarrhea - therapy | Constipation - therapy | Incretins - adverse effects | Sitagliptin Phosphate - therapeutic use | Glucagon-Like Peptides - therapeutic use | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Glucagon | Diabetes mellitus | Body weight | Hemoglobin | Diabetes | Safety | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Index Medicus | Original
Journal Article
Diabetic medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
Aims To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people... 
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Index Medicus | Complications | Research
Journal Article
Enzyme and microbial technology, ISSN 0141-0229, 01/2019, Volume 120, pp. 52 - 60
Journal Article
Journal Article